To the full analysis
Buyback calculator for PharmaEssentia
PharmaEssentia stock: key metrics
6446.TWPharmaEssentia had an operating margin of 31.5% and a return on invested capital (ROIC) of 56.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2010 | 48.0% | −311.8% | −315.0% |
| 2011 | −54.2% | −1,312.4% | −1,292.4% |
| 2012 | 69.3% | −880.2% | −899.3% |
| 2013 | 93.0% | −831.0% | −820.1% |
| 2014 | 55.2% | −6,465.0% | −6,387.4% |
| 2015 | −262.9% | −7,436.8% | −7,362.2% |
| 2016 | 79.2% | −15,506.7% | −15,437.9% |
| 2017 | 106.5% | −22,044.0% | −21,618.5% |
| 2018 | −8.2% | −4,020.8% | −3,963.1% |
| 2019 | 79.8% | −277.8% | −275.8% |
| 2020 | 33.0% | −307.9% | −349.6% |
| 2021 | 42.3% | −429.9% | −428.2% |
| 2022 | 71.8% | −70.4% | −47.7% |
| 2023 | 88.0% | −37.5% | −12.2% |
| 2024 | 87.9% | 17.8% | 30.5% |
| 2025 | 87.5% | 31.5% | 32.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2010 | −68.5% | −65.5% | −53.9% |
| 2011 | −100.0% | no data | −54.0% |
| 2012 | −46.6% | −63.8% | −34.9% |
| 2013 | −27.9% | −35.1% | −26.9% |
| 2014 | −58.1% | −36.7% | −51.4% |
| 2015 | −100.0% | −56.9% | −82.0% |
| 2016 | −19.8% | −25.8% | −18.8% |
| 2017 | −25.2% | −17.7% | −23.8% |
| 2018 | −42.1% | −27.1% | −37.1% |
| 2019 | −37.4% | −79.4% | −28.5% |
| 2020 | −49.7% | −38.0% | −35.2% |
| 2021 | −66.1% | −47.9% | −45.4% |
| 2022 | −11.3% | −67.6% | −9.0% |
| 2023 | −2.6% | −34.0% | −2.3% |
| 2024 | 10.8% | 26.8% | 9.5% |
| 2025 | 15.8% | 56.4% | 13.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = NT$32.8500)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.